Literature DB >> 12857988

Rational approaches to immune regulation.

Yvonne Paterson1.   

Abstract

Our laboratory is interested in the properties of proteins that render them immunogenic, and how such immunogenicity may be modulated in vivo. We are attempting to enhance the immune response in the design of more effective vaccines against viral diseases, such as HIV, and against tumor antigens expressed on breast, ovarian, and cervical cancer and B cell lymphomas. Our main approach is to use a facultative intracellular bacterium, Listeria monocytogenes, which has the unusual ability to live and grow in the cytoplasm of the cell and is thus an excellent vector for targeting passenger antigens to the major histocompatibility complex (MHC) class I pathway of antigen processing with the generation of authentic cytotoxic T lymphocytes (CTL) epitopes. In the field of tumor immunotherapy, we are also developing nonliving vaccine vectors for tumor antigens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12857988     DOI: 10.1385/IR:27:2-3:451

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   4.505


  60 in total

Review 1.  B7-1 gene-modified tumor cell vaccines.

Authors:  S J Antonia
Journal:  Curr Opin Mol Ther       Date:  1999-02

Review 2.  Delivery of DNA vaccines by attenuated intracellular bacteria.

Authors:  G Dietrich; I Gentschev; J Hess; J B Ulmer; S H Kaufmann; W Goebel
Journal:  Immunol Today       Date:  1999-06

3.  The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine comprises multiple effector mechanisms.

Authors:  L M Weiskirch; Z K Pan; Y Paterson
Journal:  Clin Immunol       Date:  2001-03       Impact factor: 3.969

4.  Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?

Authors:  Paul Andrew Antony; Nicholas P Restifo
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

5.  The relationship between humoral and cell-mediated immunity.

Authors:  C R Parish
Journal:  Transplant Rev       Date:  1972

6.  HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins.

Authors:  F Michel; A Hoffenbach; P Froussard; P Langlade-Demoyen; M Kaczorek; M P Kieny; F Plata
Journal:  AIDS Res Hum Retroviruses       Date:  1992-04       Impact factor: 2.205

7.  Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine.

Authors:  Z K Pan; G Ikonomidis; D Pardoll; Y Paterson
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

8.  Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein.

Authors:  F Buseyne; M McChesney; F Porrot; S Kovarik; B Guy; Y Rivière
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

9.  Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.

Authors:  B D Walker; C Flexner; K Birch-Limberger; L Fisher; T J Paradis; A Aldovini; R Young; B Moss; R T Schooley
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes.

Authors:  G Ikonomidis; Y Paterson; F J Kos; D A Portnoy
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  5 in total

1.  Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes.

Authors:  Daniela I M Loeffler; Christoph U Schoen; Werner Goebel; Sabine Pilgrim
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Growth, virulence, and immunogenicity of Listeria monocytogenes aro mutants.

Authors:  Jochen Stritzker; Jozef Janda; Christoph Schoen; Marcus Taupp; Sabine Pilgrim; Ivaylo Gentschev; Peter Schreier; Gernot Geginat; Werner Goebel
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

3.  Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.

Authors:  Laurence M Wood; Patrick D Guirnalda; Matthew M Seavey; Yvonne Paterson
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  Lm-LLO-Based Immunotherapies and HPV-Associated Disease.

Authors:  Anu Wallecha; Chris French; Robert Petit; Reshma Singh; Ashok Amin; John Rothman
Journal:  J Oncol       Date:  2012-02-02       Impact factor: 4.375

5.  Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression.

Authors:  Xiulan Liu; Zhongshi Zhou; Qi Cheng; Hongjie Wang; Hui Cao; Qianqian Xu; Yali Tuo; Li Jiang; You Zou; Hongyu Ren; Ming Xiang
Journal:  Cell Death Dis       Date:  2017-09-07       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.